RT Journal Article SR Electronic T1 Immune enhancement to prevent infected pancreatic necrosis: A double-blind randomized controlled trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.08.09.21261580 DO 10.1101/2021.08.09.21261580 A1 Ke, Lu A1 Zhou, Jing A1 Mao, Wenjian A1 Chen, Tao A1 Zhu, Yin A1 Pan, Xinting A1 Mei, Hong A1 Singh, Vikesh A1 Buxbaum, James A1 Doig, Gordon A1 He, Chengjian A1 Gu, Weili A1 Lu, Weihua A1 Tu, Shumin A1 Ni, Haibin A1 Zhang, Guoxiu A1 Zhao, Xiangyang A1 Sun, Junli A1 Chen, Weiwei A1 Song, Jingchun A1 Shao, Min A1 Tu, Jianfeng A1 Xia, Liang A1 He, Wenhua A1 Zhu, Qingyun A1 Li, Kang A1 Yao, Hongyi A1 Wu, Jingyi A1 Fu, Long A1 Jiang, Wendi A1 Zhang, He A1 Lin, Jiajia A1 Li, Baiqiang A1 Tong, Zhihui A1 Windsor, John A1 Liu, Yuxiu A1 Li, Weiqin A1 Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG) YR 2021 UL http://medrxiv.org/content/early/2021/08/10/2021.08.09.21261580.abstract AB BACKGROUND&AIMS Infected pancreatic necrosis (IPN) is a highly morbid complication of acute pancreatitis (AP). Since there is evidence of immunosuppression in the early phase of AP, immune enhancement using Thymosin alpha 1 (Tα1), which stimulates both innate and adaptive immunity, may be a therapeutic strategy to prevent IPN. Our aim was to assess the efficacy of early Tα1 treatment on the development of IPN.METHODS We conducted a multicenter, randomized, double-blind, placebo-controlled trial in patients with predicted severe acute necrotizing pancreatitis (ANP). ANP patients with an APACHE II score≥8 admitted within seven days of the advent of symptoms were considered eligible. Enrolled patients were assigned to receive a subcutaneous injection of Tα1 1.6 mg, every 12 hours for the first 7 days and 1.6 mg once a day for the subsequent 7 days or matching placebo (normal saline). The primary outcome was the development of IPN during the index admission.RESULTS From Mar 2017 through Dec 2020, 508 patients were randomized at 16 hospitals, of whom 254 were assigned to receive Tα1 and 254 placebo. During the index admission, 40/254 (15.7%) patients in the Tα1 group developed IPN compared with 46/254 patients (18.1%) in the placebo group (difference -2.4% [95%CI -7.4% to 5.0%]; p=0.47). The results were similar in four predefined subgroups. There was no difference in other major complications, including new-onset organ failure (10.6% vs. 15.0%; p=0.15), bleeding (6.3% vs. 3.5%; p=0.15), and gastrointestinal fistula (2.0% vs. 2.4%; p=0.75) during the index admission.CONCLUSIONS The immune-enhancing Tα1 treatment of patients with predicted severe ANP did not reduce the incidence of IPN during the index admission.Trial registration Clinicaltrials.gov registry: NCT02473406.Competing Interest StatementDr. Weiqin Li reports consultancy fees and grants from SciClone Pharmaceuticals. Dr. Zhihui Tong reports speaker fees from SciClone Pharmaceuticals. Dr. Lu Ke reports speaker fees frees from SciClone Pharmaceuticals. The other authors have no relevant conflict of interest to declare. Dr. Vikesh Singh reports consultant fees and grants Abbvie, medical advisory board participant for Envara, and grants from Theraly and Orgenesis.Clinical TrialClinicaltrials.gov registry: NCT02473406.Clinical Protocols https://bmjopen.bmj.com/content/10/9/e037231.long Funding StatementThis study was funded by SBE2016750187 of Science and technology project, Jiangsu Province, China, partly by SciClone Pharmaceuticals Holding Limited. The funders were not involved in the trial's design, data collection, interpretation, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the ethics committee of Jinling hospital (2015NZKY-004-02) and registered on the ClinicalTrials.gov Registry (NCT02473406) before enrollment commenced.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.ANPacute necrotizing pancreatitisAPacute pancreatitisCRPC-reactive proteinGLMgeneralized linear modelIPNinfected pancreatic necrosisITTintention-to-treatmHLA-DRmonocyte human leukocyte antigen-DRPPper-protocolRACRevised Atlanta ClassificationTα1Thymosin alpha 1